Mereo BioPharma Group plc

Director's Dealing • Oct 2, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5661O

Mereo BioPharma Group plc

02 October 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of PDMR Dealing

London, October 02, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on September 30, 2019, John Richard, Head of Corporate Development, purchased 1500 American Depositary Shares (ADSs) at a price of USD2.96 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

PURCHASE OF ADS

c)

Price(s) and volume(s)

Price(s)	Volume(s)
USD 2.96	1500

d)

Aggregated information:  volume, Price

Aggregated volume: 1500

Aggregated price: USD2.958

e)

Date of the transaction

2019-09-30

f)

Place of the transaction

XNMS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBSBDGBUGBGCD